Investor Presentation for Audited Financial Results/Statements for the Quarter and Financial Year ended March 31, 2026.

Mgmt Guided Margin ImprovementPromoter Disclosed Acquisition PlansAnalyst Day Multiyear TargetsInvestor Communications View source PDF

ENTERO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-9.9%1-day move

₹1311.00

prior close

₹1358.90

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-3.5-3.8-2.3-4.7-9.9-8.5-13.7-11.9-14.5-14.6-15.3-8.5-2.6—

Up moveDown movePending

AI summary

Entero Healthcare Solutions reported strong FY26 results with revenue of Rs 6,591 Cr (up 29.3% YoY) and EBITDA margin expanding to 4.0% from 3.4% in FY25. The company achieved LFL revenue growth of 31.5%, exceeding its 30% guidance. Q4FY26 was particularly strong with revenue up 42.6% YoY and EBITDA margin at 4.5%. Operating cashflow turned positive at Rs 96.2 Cr vs negative Rs 76.9 Cr in FY25. Seven acquisitions were closed during the year including three MedTech acquisitions, with MedTech revenue expected to cross Rs 1,000 Cr in FY27. ROCE improved significantly to 14.6% from 10.7%.

Likely market impact

The company delivered ahead of guidance on all parameters with margin expansion and cashflow turnaround demonstrating improved business quality. FY27 guidance of 23% revenue growth, 5% EBITDA margin, and 50% OCF-to-EBITDA conversion signals continued confidence in execution and consolidation strategy.